Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2019.00248/full |
| _version_ | 1828848105129246720 |
|---|---|
| author | Mehdi Mirsaeidi Pamela Barletta Marilyn K. Glassberg |
| author_facet | Mehdi Mirsaeidi Pamela Barletta Marilyn K. Glassberg |
| author_sort | Mehdi Mirsaeidi |
| collection | DOAJ |
| description | A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD. |
| first_indexed | 2024-12-12T22:23:28Z |
| format | Article |
| id | doaj.art-e5032a21e8c948afadbb1a023916faed |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-12T22:23:28Z |
| publishDate | 2019-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-e5032a21e8c948afadbb1a023916faed2022-12-22T00:09:50ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2019-10-01610.3389/fmed.2019.00248465053Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease ManagementMehdi MirsaeidiPamela BarlettaMarilyn K. GlassbergA subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.https://www.frontiersin.org/article/10.3389/fmed.2019.00248/fullsclerodermainterstitial lung diseasesystemic sclerosiscyclophosphamidenintedanibpirfenidone |
| spellingShingle | Mehdi Mirsaeidi Pamela Barletta Marilyn K. Glassberg Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management Frontiers in Medicine scleroderma interstitial lung disease systemic sclerosis cyclophosphamide nintedanib pirfenidone |
| title | Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management |
| title_full | Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management |
| title_fullStr | Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management |
| title_full_unstemmed | Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management |
| title_short | Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management |
| title_sort | systemic sclerosis associated interstitial lung disease new directions in disease management |
| topic | scleroderma interstitial lung disease systemic sclerosis cyclophosphamide nintedanib pirfenidone |
| url | https://www.frontiersin.org/article/10.3389/fmed.2019.00248/full |
| work_keys_str_mv | AT mehdimirsaeidi systemicsclerosisassociatedinterstitiallungdiseasenewdirectionsindiseasemanagement AT pamelabarletta systemicsclerosisassociatedinterstitiallungdiseasenewdirectionsindiseasemanagement AT marilynkglassberg systemicsclerosisassociatedinterstitiallungdiseasenewdirectionsindiseasemanagement |